BREAST CANCER

Browse all BREAST CANCER
T-DXd Plus Pertuzumab and New Data in HER2+ Metastatic Breast Cancer

BREAST CANCER

T-DXd Plus Pertuzumab and New Data in HER2+ Metastatic Breast Cancer

Sara Tolaney, MD, MPH, Rohit Gosain, MD, Rahul Gosain, MD, MBA

HEMATOLOGY

Browse all HEMATOLOGY
Teclistamab Plus Daratumumab Approved for Relapsed or Refractory Multiple Myeloma After MajesTEC-3

HEMATOLOGY

Teclistamab Plus Daratumumab Approved for Relapsed or Refractory Multiple Myeloma After MajesTEC-3

Luciano Costa, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

AQUILA Trial Insights: Daratumumab for the Treatment of High-Risk Smoldering Myeloma

HEMATOLOGY

AQUILA Trial Insights: Daratumumab for the Treatment of High-Risk Smoldering Myeloma

S. Vincent Rajkumar, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

EPCORE FL-1: Epcoritamab Plus Lenalidomide and Rituximab for Follicular Lymphoma

HEMATOLOGY

EPCORE FL-1: Epcoritamab Plus Lenalidomide and Rituximab for Follicular Lymphoma

Gilles Salles, MD, PhD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

KOMET-001 Leads to Ziftomenib Approval for NPM1-Mutated AML

HEMATOLOGY

KOMET-001 Leads to Ziftomenib Approval for NPM1-Mutated AML

Eunice Wang, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

GU ONCOLOGY

Browse all GU ONCOLOGY
Transformative Data in Cisplatin-Ineligible MIBC: Clinical Implications of Enfortumab Vedotin Plus Pembrolizumab

GU ONCOLOGY

Transformative Data in Cisplatin-Ineligible MIBC: Clinical Implications of Enfortumab Vedotin Plus Pembrolizumab

Thomas Powles, MD, MBBS, MRCP, Rahul Gosain, MD, MBA, Rohit Gosain, MD

The Promise of Anktiva: Expert Insight on IL-15 Therapy in Cancer Care

GU ONCOLOGY

The Promise of Anktiva: Expert Insight on IL-15 Therapy in Cancer Care

Patrick Soon-Shiong, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Perioperative Durvalumab FDA Approval New Standard for Muscle Invasive Bladder Cancer

GU ONCOLOGY

Perioperative Durvalumab FDA Approval New Standard for Muscle Invasive Bladder Cancer

Thomas Powles, MD, MBBS, MRCP

GI ONCOLOGY

Browse all GI ONCOLOGY
Durvalumab Approved For Resectable Upper Gastrointestinal Cancers

GI ONCOLOGY

Durvalumab Approved For Resectable Upper Gastrointestinal Cancers

Yelena Janjigian, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

FDA Approval of Cabozantinib in Neuroendocrine Tumors

GI ONCOLOGY

FDA Approval of Cabozantinib in Neuroendocrine Tumors

Aman Chauhan, MD

LUNG CANCER

Browse all LUNG CANCER
FDA Approval of Zongertinib in HER2-Mutated NSCLC

LUNG CANCER

FDA Approval of Zongertinib in HER2-Mutated NSCLC

Joshua Sabari, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

FDA Approves Dato-DXd for Patients With EGFR-Mutated NSCLC

LUNG CANCER

FDA Approves Dato-DXd for Patients With EGFR-Mutated NSCLC

Jacob Sands, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD